Columbus, IN

Pankratz Eye Institute

Keratoconjunctivitis Sicca

Dry Eye Syndromes

Eye Diseases

Blepharitis

PL9643

AR-15512

AZR-MD-001

TP-03

Aerie Pharmaceuticals

Azura Ophthalmics

Palatin Technologies

Tarsus Pharmaceuticals

condition

allSponsorName

Ora, Inc.

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Pankratz Eye Institute | Columbus, IN

Site insights

Work at this site?

Active trials

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Trial sponsors